Fenfluramine potentiates canine pulmonary vasoreactivity to endothelin-1

Pulmonary Pharmacology and Therapeutics

Volumn 11, Issue 2-3, 1998, Pages 183-187

  Barman, S A ^a   Isales, C M ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Endothelin 1; Fenfluramine; Pulmonary vascular resistance; Pulmonary vasoconstriction; Serotonin

Indexed keywords

ENDOTHELIN 1; FENFLURAMINE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD VESSEL REACTIVITY; CAPILLARY RESISTANCE; CONFERENCE PAPER; CONTROLLED STUDY; DOG; FEMALE; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG CIRCULATION; LUNG PERFUSION; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

EID: 0032056050     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.1998.0135     Document Type: Conference Paper

References (30)

1. 1. Saxena P R, Wallis D I, Wouters W. Cardiovascular pharmacology of 5-hydroxytryptamine. In: Bevan P, ed. Cardiovascular Pharmacology of 5-Hydroxytryptamine: Prospective Therapeutic Applications. Dordrecht, The Netherlands, Kluwer Academic, 1990: 101-119.
2. 2. El-Kashef H A, Hofman W F, Ehrhart I C. Verapamil inhibition of serotonin-induced vasoconstriction in dog lung. J Cardiovasc Pharmacol 1990; 15: 729-735.
3. 3. Hofman W F, Ehrhart I C. Effects of cyclooxygenase inhibition on pulmonary vascular response to serotonin. J Appl Physiol 1987; 62: 1192-1200.
4. 4. Rippe B, Parker J C, Townsley M, Mortillaro N A, Taylor A E. Segmental vascular resistances and compliances in dog lung. J Appl Physiol 1987; 62: 1206-1215.
5. 5. Barman S A, Pauly J R, Isales C M. Canine pulmonary vasoreactivity to serotonin: role of protein kinase C and tyrosine kinase. Am J Physiol 1997; 272: H740-H747.
6. 6. McMahon T J, Hood J S, Nossaman B D, Kadowitz P J. Analysis of responses to serotonin in the pulmonary vascular bed of the cat. J Appl Physiol 1993; 75: 93-102.
7. 2 serotonergic receptors. J Pharmacol Exp Ther 1981; 218: 271-303.
8. 8. Rowland N E. Dexfenfluramine. Lancet 1991; 337: 1315-1316.
9. 9. Weir E K, Reeve H L, Huang J M C, Michelakis E, Nelson D P, Hampl V, Archer S L. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996; 94: 2216-2220.
10. 10. Engelhardt A, Kroneberg G, Stoepel K, Stotzer H. The effects of acute and chronic administration of sympathomimetic substances on the systemic and pulmonary circulation. Proc Eur Soc Drug Toxicol 1970; 11: 110-117.
11. 11. Miczoch J, Weir E K, Reeves J, Grover R. Long term effects of the anoretic agent fenfluramine alone and in combination with aminorex on pulmonary and systemic circulation in the pig. Basic Res Cardiol 1979; 74: 313-320.
12. 12. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simoneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70: 537-541.
13. 13. Hunsinger R N, Wright D. A characterization of the acute cardiopulmonary toxicity of fenfluramine in the rat. Pharmacol Res 1990; 22: 371-378.
14. 14. Naeije R, Wauthy P, Maggiorini M, Leeman M, Delcroix M. Effects of dexfenfluramine on hypoxic pulmonary vasoconstriction and embolic pulmonary hypertension in dogs. Am J Respir Crit Care Med 1995; 151: 692-697.
15. 15. Barman S A, Pauly J R. Mechanism of action of endothelin-1 in the canine pulmonary circulation. J Appl Physiol 1995; 79: 2014-2020.
16. 16. Miller V M, Komori K, Burnett J C, Vanhoutte P M. Differential sensitivity to endothelin in canine arteries and veins. Am J Physiol 1989; 257: H1127-H1131.
17. 17. Stewart D J, Levy R D, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Inter Med 1991; 114: 464-469.
18. 18. Barman S A, Taylor A E. Histamine's effect on pulmonary vascular resistance and compliance at elevated tone. Am J Physiol 1989; 257: H618-H625.
19. c,i in lung and skeletal muscle. J Appl Physiol 1986; 61: 127-132.
20. 2+ mechanisms defective in cholestasis. J Clin Invest 1992; 92: 2984-2993.
21. 21. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-615.
22. 22. Rubin L J. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
23. 23. Cody R J, Haas G J, Binkley P F, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992: 85: 504-509.
24. 24. Yamamoto K, Ikeda U, Mito H, Fujikawa H, Sekiguchi H, Shimada K. Endothelin production in pulmonary circulation of patients with mitral stenosis. Circulation 1994; 89: 2093-2098.
25. 25. Stelzner T J, O'Brien R F, Yanagisawa M, Sakurai T, Sato K, Webb S, Zamora M, McMurtry I F, Fisher J H. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol 1992; 262: L614-L620.
26. 2+ channels by serotonin 2 receptor stimulation in vascular smooth muscle cells. Am J Physiol 1995; 268: H544-H549.
27. 27. Tolloczko B, Jia L, Martin J G. Serotonin-evoked calcium transients in airway smooth muscle cells. Am J Physiol 1995; 269: L234-L240.
28. 28. Wang H Y, Friedman E. Central 5-hydroxytryptamine receptor-linked protein kinase C translocation: A functional postsynaptic signal transduction system. Mol Pharmacol 1990; 37: 75-79.
29. 29. Forder J, Scriabine A, Rasmussen H. Plasma membrane calcium flux, protein kinase C activation, and smooth muscle contraction. J Pharmacol Exp Ther 1985; 235: 267-273.
30. 30. Rasmussen H, Calle R, Ganesan S, Smallwood J, Throckmorton D, Zawalich W. Protein kinase C: Role in sustained cellular responses. In: Epand R, Lester D, eds. Protein Kinase C: Current Concepts and Future Perspectives. Chichester, England: Ellis Horwood, 1991: 73-100.